Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development
Authors:
- 27 May 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 102 (2) , 290-296
Abstract
In 2008, the US Food and Drug Administration (FDA) issued guidance on the need for cardiovascular outcome trials to assess the safety of new diabetes medications. Using two large commercial databases, we evaluated the effect of the FDA's cardiovascular safety guidance on drug development for type 2 diabetes as well as a comparison group of drugs intended to treat other alimentary and metabolic conditions. The FDA's guidance was associated with a 31% differential decrease in the rate of diabetes drugs entering phase II trials, but the remaining drugs were significantly more likely to target novel biological pathways (72% of drugs had novel mechanisms after the guidance vs. 49% before the guidance). No differential changes were observed for phase I and phase III trials. There was no measurable improvement during the study period in glycemic efficacy among investigational products entering phase III trials. This research highlights how regulatory actions can impact pharmaceutical innovation.Keywords
This publication has 32 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Quantifying The Food And Drug Administration’s Rulemaking Delays Highlights The Need For TransparencyHealth Affairs, 2014
- Life Cycle of Medical Product Rules Issued by the US Food and Drug AdministrationJournal of Health Politics, Policy and Law, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to PracticeCurrent Cardiology Reports, 2011
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular OutcomesNew England Journal of Medicine, 2011
- Licensing drugs for diabetesBMJ, 2010
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or PioglitazoneJAMA, 2010
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005